Bone Biologics EPS BBLG
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$1.61
- Latest quarter, Q2 FY26
- −$0.43
- Fiscal year 2025
- −$4.00
Bone Biologics' earnings per share was −$1.61 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.43.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.00 | n/a |
| FY2024 | −$29.78 | n/a |
| FY2023 | −$412.20 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$648.00 | n/a |
| FY2020 | −$806.40 | n/a |
| FY2019 | −$13536.00 | n/a |
| FY2018 | −$29664.00 | n/a |
| FY2017 | −$53856.00 | n/a |
| FY2016 | −$164160.00 | n/a |
| FY2015 | −$132480.00 | n/a |
| FY2014 | n/a | n/a |
| FY2013 | n/a | n/a |
| FY2013 | n/a | n/a |
| FY2012 | $0.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.43 | n/a | −$1.61 | |
| Q1 FY26 | −$0.43 | n/a | −$2.51 | |
| Q4 FY25 | −$0.38 | n/a | −$4.00 | |
| Q3 FY25 | −$0.37 | n/a | −$7.31 | |
| Q2 FY25 | −$1.33 | n/a | −$21.15 | |
| Q1 FY25 | −$1.92 | n/a | −$23.84 | |
| Q4 FY24 | −$3.69 | n/a | −$29.78 | |
| Q3 FY24 | −$14.21 | n/a | −$46.43 | |
| Q2 FY24 | −$4.02 | n/a | −$61.62 | |
| Q1 FY24 | −$7.86 | n/a | −$88.86 | |
| Q4 FY23 | −$20.34 | −123% | −$412.20 | |
| Q3 FY23 | −$29.40 | n/a | −$303.54 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Bone Biologics' size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| BBLGBone Biologics | −$1.61 |
| VJETFlyte Aviation | n/m |
| IVFINVO Fertility | n/m |
| TNONTenon Medical | −$25.65 |
| XAIRBeyond Air | −$68.40 |
| ADGMAdagio Medical | −$1.43 |
| PFSAProfusa | n/m |
| AMIXAutonomix Medical | n/m |
| NXGLNexgel | −$14.20 |
| BJDXBluejay Diagnostics | −$8.68 |
| VVOSVivos Therapeutics | −$1.88 |
| Peer median | −$11.44 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bone Biologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.